Research finds new small molecule drugs that regulate brown adipose tissue activity October 24, 2018 Source: Chinese Academy of Sciences On October 20th, EBioMedicine published the results of a collaborative study between the Ding Qiurong Research Group of the Shanghai Institutes for Biological Sciences (Nutrition and Health Institute) and the Shanghai University of Traditional Chinese Medicine Lao Yuanzhi Research Group. “Screening of FDA-approved drugs identification sutent as a Modulator of UCP1 expression in brown adipose tissue". In this study, large-scale compound screening revealed that sutent, as a new small molecule that activates Brown Adipose Tissue (BAT), is a potential drug for the treatment of obesity and fatty liver and other related metabolic diseases. Obesity is a chronic metabolic disease caused by a variety of factors. The body fat percentage is abnormally increased by the increase in the volume and number of white fat cells in the body, and is characterized by excessive deposition of fat in some areas. The current anti-obesity drugs mainly limit energy intake by reducing fat absorption or suppressing appetite. However, the clinical effect is not very obvious, and there are side effects, and there is no clinically effective drug for treating obesity by increasing energy utilization. Brown fat increases energy consumption compared to the function of white fat to store heat. In addition to being present in human infancy, brown fat has also been found in adult bodies in recent years, suggesting that energy can be consumed as heat by increasing the heat production function of brown adipose tissue, which can be used as a target for the treatment of obesity and related metabolic diseases. point. In order to find small molecules that activate brown fat cells, Ph.D. students Qiu Yanhe and postdoctoral Dr. Sun Yingmin and others set a green fluorescent protein (GFP) expression box at the stop of the brown fat mature marker uncoupling protein (UCP1) stop codon. Mature brown fat lineage-labeled mouse brown adipocyte reporter strain. On this basis, a large-scale compound screening was conducted for more than 1,000 clinical drugs that have been approved by the FDA, and 42 small molecule drugs that promote the up-regulation of UCP1 in brown fat cells were found. Further in vivo validation experiments found that one of the small molecule drugs, Suotan, significantly promoted UCP1 expression in mouse brown adipocytes in vitro; after oral administration, Sotan could activate brown adipose tissue in mice, increase energy expenditure, and simultaneously inhibit White fat and fat synthesis in the liver significantly resists obesity induced by a high-fat diet and relieves fatty liver symptoms. The study comprehensively reports the establishment of a highly efficient in vitro cell assay system for screening and regulating small molecules that activate brown fat cells through gene cell lines and large-scale compound screening, and also provides potential for small obesity and related metabolic diseases. Molecular drugs. The research was supported by the National Key Research and Development Program, the Chinese Academy of Sciences Stem Cell Pilot Project, the National Natural Science Foundation of China, and the Shanghai Nutrition and Health Institute's public technology platform. Figure: Screening of a small molecule compound library by Ucp1-GFP adipocyte strain, and finding a drug that can significantly promote the expression of UCP1, Sutent, can be promoted in vitro and in vivo using mouse model animals. Non-shivering heat production and inhibition of lipid synthesis to resist obesity induced by a high-fat diet and improve body metabolism. Double Breast Pump Electric,Silicone Breast Pump,Double Breast Pump,Bpa Free Breast Pump NINGBO YOUHE MOTHER&BABY PRODUCTS CO.,LTD , https://www.oembreastpump.com
Research finds new small molecule drugs that regulate brown adipose tissue activity